Loading...
•
Mar 31
Krystal Biotech Q1 2025 Earnings Report
Estimated Revenue:$96.3M
+107.3% YoY
Estimated EPS:$1.36
+813.3% YoY
Key Takeaways
Krystal Biotech reported strong first-quarter 2025 results driven by VYJUVEK revenue, achieving $88.2 million in product sales and a net income of $35.7 million. The company also secured European approval for VYJUVEK and advanced its pipeline with a new ophthalmic program and upcoming clinical readouts.
VYJUVEK approved in Europe for the treatment of DEB patients from birth
$88.2 million in 1Q VYJUVEK revenue and $429.4 million since launch in Q3 2023
Second ophthalmic program in clinic - KB801 for the treatment of neurotrophic keratitis
Upcoming clinical readouts in 2025 - CF, AATD, ocular complications of DEB, and aesthetics
Krystal Biotech
Krystal Biotech
Krystal Biotech Revenue by Segment
Revenue by Segment
VYJUVEK Net Product Revenue
CapyFin.com Forward Guidance
The company provided guidance for full-year 2025 non-GAAP combined R&D and SG&A expenses, expecting them to be between $150 million and $175 million, excluding stock-based compensation.
Positive Outlook
- First European launch of VYJUVEK in Germany expected in mid-2025.
- Potential expansion to Japan later in the year with a PMDA decision expected in 2H 2025.
- Near-term initiation of registrational study in DEB patients with eye lesions (KB803 Phase 3 IOLITE).
- Dosing the first patient in the KB801 Phase 1/2 EMERALD-1 study expected later this month.
- Upcoming clinical readouts in 2025 for CF (KB407), AATD (KB408), ocular complications of DEB (KB803), and aesthetics (KB304).
Challenges Ahead
- Non-GAAP R&D and SG&A expense guidance excludes stock-based compensation, which is difficult to estimate.
- GAAP R&D and SG&A expense guidance is not provided due to the uncertainty of stock-based compensation.
- Uncertainties exist regarding regulatory review timelines and outcomes for clinical trials and marketing approvals.
- The availability or commercial potential of VYJUVEK or other product candidates is uncertain.
- Future results may differ materially from forward-looking statements due to various factors.
Loading...
Key Statistics
Market Cap
$4.27B
P/E Ratio
32.31
Sector
Health Technology
Industry
Biotechnology
52-Week High
$201
52-Week Low
$123
VYJUVEK Net Product Revenue
$88.2M
VYJUVEK Gross Margin
94%
VYJUVEK Reimbursement Approvals
540
VYJUVEK Patient Compliance
83%
R&D Expenses
$14.3M